Regeneron and Sanofi’s checkpoint inhibitor Libtayo (cemiplimab-rwlc) won U.S. Food and Drug Administration approval for the first-line treatment of patients with advanced non-small cell lung cancer whose tumors have high PD-L1 expression.

The U.S. Food and Drug Administration approved Merck’s anti-PD-1 therapy Keytruda as monotherapy for the treatment of patients with recurrent or metastatic cutaneous squamous cell carcinoma (cSCC) that is not curable by surgery or radiation.

Researchers at Boston University and Signify confirmed that UV-C light effectively eradicates the SARS-CoV-2 virus.

Pluristem Therapeutics Inc. reported positive results from a series of studies in animals of the company’s placenta-based stem cell therapy to treat acute radiation syndrome (ARS).

Switzerland will introduce a monitoring system to assuage concerns about the potential health impact of fifth-generation (5G) mobile frequency emissions and smooth the cutting-edge technology’s rollout, the government said.

To prepare for radiological and nuclear emergencies, the U.S. Department of Health and Human Services (HSS) announced it will work with Argentum Medical LLC to repurpose the company’s commercial Silverlon technology for radiation injuries of the skin.

AstraZeneca’s immunotherapy drug Imfinzi was approved in Europe for use in lung cancer patients with inoperable disease that had advanced locally but not spread widely around the body.

The escalating threat of a potential nuclear war between North Korea and the United States has led the Department of Defense to join hands with a clutch of companies in developing more effective medical treatments for acute radiation syndrome.

Boston Scientific called a single pacemaker-related death for its S-ICD implant a “fluke” that was the result of radiation corruption that negatively impacted the device’s memory.

Bayer AG is packing more cancer drugs into its pipeline to gain a bigger share of the almost $100 billion global market for such treatments. Known for Aspirin and the blood thinner Xarelto, Germany’s most valuable company had no cancer treatments on the market a decade ago. By the end of this one, Bayer may […]